A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):373-82. doi: 10.1016/j.jchromb.2008.09.013. Epub 2008 Sep 19.

Abstract

An LC/MS/MS method was developed to quantify carboplatin and eribulin mesylate (E7389) in human plasma and urine. For carboplatin, sample clean-up by protein precipitation and supernatant injection into a Waters Spherisorb((R)) S5 SCX column was used. Liquid-phase extraction and reverse-phase chromatography on a Polaris C18 column were used for eribulin. Quantitation involved LC/MS/MS with positive electrospray ionization. Accuracy, precision, linearity, range, specificity, recovery and stability were also evaluated. Both compounds were stable in human plasma (>or=80 days at -80 degrees C), at room temperature (>or=4h), following three freeze-thaw cycles and in 50/50 methanol/H(2)O (<4 degrees C for >or=252 days).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / urine
  • Carboplatin / blood*
  • Carboplatin / urine
  • Chromatography, High Pressure Liquid / methods*
  • Drug Stability
  • Furans / blood*
  • Furans / urine
  • Humans
  • Ketones / blood*
  • Ketones / urine
  • Linear Models
  • Reference Standards
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectrometry, Mass, Electrospray Ionization / methods
  • Tandem Mass Spectrometry / methods*
  • Tolbutamide / analysis

Substances

  • Antineoplastic Agents
  • Furans
  • Ketones
  • Tolbutamide
  • Carboplatin
  • eribulin